- $581.07m
- $528.01m
- $52.23m
Brief: Brainsway Announces Minority-Stake Investment In Hopemark Health
Brief: Brainsway Announces New Minority-Stake Investment In Canadian Provider, Brainstim Health Inc.
Brief: Brainsway Announces Change In ADS-To-Ordinary Share Ratio
Brief: BrainsWay Announces FDA Approval of Neurolief’s Proliv™Rx Neuromodulation System for Major Depressive Disorder (MDD)
Brief: Brainsway Launches First Clinical Trial Of Deep Tms 360™ System For Alcohol Use Disorder
Brief: BrainsWay Receives FDA Clearance of Deep TMS as Adjunct Therapy for Major Depressive Disorder in Adolescents Aged 15 to 21
Brief: Brainsway Reports Third Quarter 2025 Financial Results And Operational Highlights
Brief: BrainsWay Announces Additional Minority-Stake Investments in Leading U.S. Mental Health Providers
Brief: BrainsWay Gets FDA Clearance for Accelerated Deep TMS Protocol to Treat Major Depressive Disorder (MDD)
Brief: BrainsWay Reports Positive Results From Multicenter Randomized Study Of Accelerated Deep TMS For Major Depressive Disorder
Brief: Brainsway Ltd Files Prospectus for Sale Of Up To 3.6 Mln American Depositary Shares
Brief: Brainsway sees full-year 2025 revenue between $49 mln to $51 mln
Brief: Jonathan Shulkin Reports 19.1% Stake In Brainsway Ltd As Of Nov 5 - SEC Filing
Brief: Brainsway Files For Mixed Shelf Of Up To $100 Mln
Brief: Brainsway Expands Global Imprint With Exclusive Multi-Year Distribution Agreement In Canada
Brief: Brainsway Launches Prospective, Randomized, Controlled, Multicenter Trial Evaluating Accelerated Deep Tms™ For Depression
Brief: Brainsway Initiates Clinical Evaluation Of Rotational Field “Deep TMS 360°™” Technology
Brief: BrainsWay Q3 EPS USD -0.01
Brief: BrainsWay Accelerates International Expansion In India